BioRestorative Therapies

BioRestorative Therapies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of BioRestorative Therapies (BRTX) as of Nov 3, 2026 is 76.57 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 92.84 % — a change of -17.53% (lower).

FCF Conversion

76.57 %

YoY

-17.53%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of BioRestorative Therapies is 2025 76.57 % . FCF Conversion Rate (FCF/EBITDA) of BioRestorative Therapies was 2024 92.84 % . It decreases by -17.53% lower compared to the previous year.

The BioRestorative Therapies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
40.88 USD
Jan 1, 2019
47.48 USD
Jan 1, 2020
17.74 USD
Jan 1, 2021
7.59 USD
Jan 1, 2022
48.05 USD
Jan 1, 2023
63.37 USD
Jan 1, 2024
92.84 USD
Jan 1, 2025
76.57 USD
The BioRestorative Therapies FCF Conversion history
YEARFCF ConversionYoY
76.57 %-17.53%
92.84 %+46.52%
63.37 %+31.87%
48.05 %+533.46%
7.59 %-57.24%
17.74 %-62.63%
47.48 %+16.13%
40.88 %+0.10%
40.84 %-32.06%
60.11 %+32.12%
45.50 %-25.14%
60.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioRestorative Therapies Stock analysis

What does BioRestorative Therapies do? BioRestorative Therapies Inc generates revenue through the development and commercialization of cell-based therapeutic products. The company focuses on two primary programs: the Disc/Spine Program (brtxDISC) and the Metabolic Program (ThermoStem). Its lead product, BRTX-100, is a cell therapy formulated from autologous cultured mesenchymal stem cells derived from patients' bone marrow, designed for non-surgical treatment of lumbosacral disc disorders. The company also develops ThermoStem, a therapy using brown adipose-derived stem cells to create brown adipose tissue for metabolic conditions like obesity and diabetes. BioRestorative Therapies targets medical professionals and healthcare institutions seeking innovative cell therapies for chronic conditions, with its products in development stages focused on specific therapeutic applications. The company’s revenue model relies on the future commercialization of BRTX-100 and ThermoStem, with no current sales reported. Its proprietary production process for BRTX-100 involves collecting bone marrow, isolating and culturing stem cells, and cryopreserving them. ThermoStem’s development targets metabolic disorders, leveraging the company’s expertise in cell and tissue protocols. BioRestorative Therapies Inc operates as a life sciences firm specializing in adult stem cell therapies, with its products positioned for potential market entry in the biotechnology sector. BioRestorative Therapies Inc’s business strategy centers on advancing its pipeline of cell-based therapies, including BRTX-100 for disc disorders and ThermoStem for metabolic conditions. The company’s focus on proprietary technology and cell culture methods differentiates its approach within the biotechnology industry. While currently in development, its products aim to address unmet medical needs, targeting healthcare providers and patients with chronic conditions requiring non-surgical interventions. BioRestorative Therapies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioRestorative Therapies stock

FCF Conversion Rate (FCF/EBITDA) of BioRestorative Therapies is 76.57 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of BioRestorative Therapies changed from 92.84 % to 76.57 %, representing a -17.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) BioRestorative Therapies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s BioRestorative Therapies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioRestorative Therapies

All Key Metrics — BioRestorative Therapies